Page last updated: 2024-08-23

alkenes and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

alkenes has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arbi, ME; Gargouri, A; Gupta, GK; Jaouen, G; Ketata, E; Mihoubi, W; Neifar, A; Pigeon, P; Top, S	1

Other Studies

1 other study(ies) available for alkenes and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Article	Year
Aryl Butenes Active against K562 Cells and Lacking Tyrosinase Inhibitory Activity as New Leads in the Treatment of Leukemia. Mini reviews in medicinal chemistry, 2018, Volume: 18, Issue:15 Topics: Alkenes; Apoptosis; Binding Sites; Catalytic Domain; Cell Proliferation; Enzyme Inhibitors; Humans; Hydrogen Bonding; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Conformation; Molecular Docking Simulation; Monophenol Monooxygenase; Tamoxifen	2018

Article

Year

Aryl Butenes Active against K562 Cells and Lacking Tyrosinase Inhibitory Activity as New Leads in the Treatment of Leukemia.

Mini reviews in medicinal chemistry, 2018, Volume: 18, Issue:15

Topics: Alkenes; Apoptosis; Binding Sites; Catalytic Domain; Cell Proliferation; Enzyme Inhibitors; Humans; Hydrogen Bonding; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Conformation; Molecular Docking Simulation; Monophenol Monooxygenase; Tamoxifen

2018